As Revlim­id sales fall, Bris­tol My­ers turns to its next mul­ti­ple myelo­ma pill that's a mol­e­c­u­lar glue

An ex­per­i­men­tal pill de­vel­oped by Bris­tol My­ers Squibb has shown promis­ing ef­fi­ca­cy in a clin­i­cal tri­al for ad­vanced mul­ti­ple myelo­ma pa­tients who have ex­haust­ed most oth­er op­tions. The drug, mezig­do­mide, is in a class of med­i­cines called “mol­e­c­u­lar glues” that has seen sub­stan­tial Big Phar­ma and VC in­vest­ment in re­cent years.

In a Phase II study with 101 pa­tients, 41% saw their can­cers re­spond to mezig­do­mide plus dex­am­etha­sone. For those pa­tients who re­spond­ed, the du­ra­tion of re­sponse was 7.6 months. All in all, pa­tients did not see their can­cers progress for a me­di­an of 4.4 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER